Clinical Efficacy and Toxicity of Anti-EGFR Therapy in Common Cancers. (6th May 2009)

• Record Type: Journal Article
• Authors: Harandi, Amir; Zaidi, Aisha S.; Stocker, Abigail M.; Laber, Damian A.
• Other Names: Chua Daniel Academic Editor.
• Is Part Of: Journal of oncology. Volume 2009(2009)
• Publication Date: 2009-05-06
• Subjects: Oncology -- Research -- Periodicals; Tumors -- Periodicals; Neoplasms; Oncology -- Research; Tumors; Periodicals; Periodicals; 616.994
• DOI: 10.1155/2009/567486
• Languages: English
• ISSNs: 1687-8450

Abstract

Abstract : Epidermal growth factor receptor (EGFR) is a cell surface molecule and member of the ErbB family of receptor tyrosine kinases. Its activation leads to proliferation, antiapoptosis, and metastatic spread, making inhibition of this pathway a compelling target. In recent years, an increasing number of clinical trials in the management of solid malignancies have become available indicating the clinical efficacy of anti-EGFR monoclonal antibodies and oral small molecule tyrosine kinase inhibitors (TKIs). This review addresses frequently used EGFR inhibitors, summarizes clinical efficacy data of these new therapeutic agents, and discusses their associated toxicity and management.